Juvenile idiopathic inflammatory myopathies with anti‐3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase antibodies in a Chinese cohort. (1st May 2021)
- Record Type:
- Journal Article
- Title:
- Juvenile idiopathic inflammatory myopathies with anti‐3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase antibodies in a Chinese cohort. (1st May 2021)
- Main Title:
- Juvenile idiopathic inflammatory myopathies with anti‐3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase antibodies in a Chinese cohort
- Authors:
- Hou, Ying
Shao, Kai
Zhao, Bing
Dai, Tingjun
Wang, Qinzhou
Zhao, Yuying
Yan, Chuanzhu
Yan, Yaping
Ma, Xiaotian
Li, Wei - Abstract:
- Abstract: Aims: To characterize the clinical and histopathological characteristics and treatment outcomes of juvenile idiopathic inflammatory myopathies (JIIMs) with anti‐3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR) antibodies in a Chinese cohort. Methods: We detected anti‐HMGCR antibodies in a series of Chinese JIIM by ELISA and indirect immunofluorescence assay on HEK293 cells, and summarized the clinical findings of these anti‐HMGCR antibody‐positive patients. Results: Of 32 JIIM patients, 5 (15.63%) were found to be anti‐HMGCR antibody‐positive. The disease duration was 1.20 ± 0.45 months. Statin exposure was not found. Four patients had skin lesions, while typical pathological features of dermatomyositis such as perifascicular atrophy or myxovirus resistance protein A expression were not found. The mean creatine kinase level was 16771.60 U/L. Among the four patients who received long‐term (10.46 ± 1.42 years) follow‐up, three exhibited favorable outcomes with prednisone and additional immunosuppressants. Conclusions: Our study indicates that anti‐HMGCR antibodies may not be rare in Chinese JIIM. These anti‐HMGCR‐positive JIIMs were characterized by acute onset, substantially elevated creatine kinase level, and skin lesions without perifascicular changes in muscle pathology. The treatment outcome is generally favorable with the combination of steroid and immunosuppressant. Abstract : Anti‐HMGCR antibody may not be rare in Chinese juvenile idiopathicAbstract: Aims: To characterize the clinical and histopathological characteristics and treatment outcomes of juvenile idiopathic inflammatory myopathies (JIIMs) with anti‐3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR) antibodies in a Chinese cohort. Methods: We detected anti‐HMGCR antibodies in a series of Chinese JIIM by ELISA and indirect immunofluorescence assay on HEK293 cells, and summarized the clinical findings of these anti‐HMGCR antibody‐positive patients. Results: Of 32 JIIM patients, 5 (15.63%) were found to be anti‐HMGCR antibody‐positive. The disease duration was 1.20 ± 0.45 months. Statin exposure was not found. Four patients had skin lesions, while typical pathological features of dermatomyositis such as perifascicular atrophy or myxovirus resistance protein A expression were not found. The mean creatine kinase level was 16771.60 U/L. Among the four patients who received long‐term (10.46 ± 1.42 years) follow‐up, three exhibited favorable outcomes with prednisone and additional immunosuppressants. Conclusions: Our study indicates that anti‐HMGCR antibodies may not be rare in Chinese JIIM. These anti‐HMGCR‐positive JIIMs were characterized by acute onset, substantially elevated creatine kinase level, and skin lesions without perifascicular changes in muscle pathology. The treatment outcome is generally favorable with the combination of steroid and immunosuppressant. Abstract : Anti‐HMGCR antibody may not be rare in Chinese juvenile idiopathic inflammatory myopathy (JIIM). These anti‐HMGCR‐positive JIIMs were characterized by acute onset, high creatine kinase level, and skin lesions without perifascicular changes in muscle pathology. The treatment outcome is generally favorable with the combination of steroid and immunosuppressant. Anti‐HMGCR antibody testing should be seen as routine test for juvenile patients. … (more)
- Is Part Of:
- CNS neuroscience & therapeutics. Volume 27:Number 9(2021)
- Journal:
- CNS neuroscience & therapeutics
- Issue:
- Volume 27:Number 9(2021)
- Issue Display:
- Volume 27, Issue 9 (2021)
- Year:
- 2021
- Volume:
- 27
- Issue:
- 9
- Issue Sort Value:
- 2021-0027-0009-0000
- Page Start:
- 1041
- Page End:
- 1047
- Publication Date:
- 2021-05-01
- Subjects:
- anti‐HMGCR antibody -- juvenile idiopathic inflammatory myopathy -- treatment outcome
Neuropharmacology -- Periodicals
Central nervous system -- Diseases -- Effect of drugs on -- Periodicals
612.8 - Journal URLs:
- http://www.blackwell-synergy.com/loi/cnsnt ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cns.13658 ↗
- Languages:
- English
- ISSNs:
- 1755-5930
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9830.140000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18454.xml